Compare Intuit Inc. (INTU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Repligen Corporation Common Stock — how do they compare? Intuit Inc. trades at $309.13 (market cap $80.56B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Intuit Inc. is far larger — about 7.2× Repligen Corporation Common Stock's market cap, and Intuit Inc. pays a 1.83% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 67 Days and Repligen Corporation Common Stock for 0 Days on average.
| INTU | RGEN | |
|---|---|---|
Market Cap | $80.56B | $11.14B |
Volume | 3,646,799 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $683.39 | $194.57 |
52-Week Low | $255.07 | $102.87 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $81.78B | $11.02B |
Dividend Yield | 1.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $305.99, up 1.07% with strong earnings momentum after beating Q4 2025 and Q1-Q2 2026 EPS estimates. The stock shows bullish technical signals with support at $302 and resistance at $312. Fundamentally, revenue grew to $18.83B in 2025 with a robust 21.29% net margin, while valuation ratios like P/E of 18.31 appear reasonable. Recent news highlights growth in QuickBooks monetization and AI initiatives, though class action lawsuits create near-term uncertainty.
Outlook remains positive with analyst consensus target of $379.68 (24% upside) and 60% buy ratings. Key opportunities include sustained revenue growth and margin expansion, while risks involve legal overhangs and competitive pressures in financial software. The stock offers attractive fundamentals but requires monitoring of lawsuit developments.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
